Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors

Lukas E. Brümmer[1 +], Stephan Katzenschlager[2 +], Sean McGrath[3], Stephani Schmitz[4], Mary Gaeddert[1], Christian Erdmann[5], Marc Bota[6], Maurizio Grilli[7], Jan Larmann[2], Markus A. Weigand[2], Nira R. Pollock[8], Aurélien Macé[9], Berra Erkosar[9], Sergio Carmona[9], Jilian A. Sacks[9], Stefano Ongarello[9], Claudia M. Denkinger[1, 10]

[+] These authors contributed equally

* Corresponding author (Claudia.Denkinger@uni-heidelberg.de)

1) Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany

2) Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany

3) Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America

4) Department of Developmental Biology, Erasmus Medical Center, Rotterdam, Netherlands

5) FH Muenster University of Applied Sciences, Muenster, Germany

6) Agaplesion Bethesda Hospital, Hamburg, Germany

7) Library, University Medical Center Mannheim, Mannheim, Germany

8) Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts, United States of America

9) FIND, Geneva, Switzerland

10) German Center for Infection Research (DZIF), partner site Heidelberg University Hospital, Heidelberg, Germany

Keywords: SARS-CoV-2; Antigen Test; PCR; meta-analysis; meta-regression

Running Title: Accuracy of point-of-care Ag-RDTs for SARS-CoV-2

ABSTRACT

Background

Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail.

Methods and findings

We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse transcription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing test sensitivity, we performed 3 different analyses using multivariate mixed-effects meta-regression models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% (95% CI 98.6 to 99.1), respectively. When manufacturer instructions were followed, sensitivity increased to 76.4% (95%CI 73.8 to 78.8). Sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values (sensitivity of 97.9% [95% CI 96.9 to 98.9] and 90.6% [95% CI 88.3 to 93.0] for Ct-values <20 and <25, compared to 54.4% [95% CI 47.3 to 61.5] and 18.7% [95% CI 13.9 to 23.4] for Ct-values ≥25 and ≥30) and was estimated to increase by 2.9 percentage points (95% CI 1.7 to 4.0) for every unit decrease in mean Ct-value when adjusting for testing procedure and patients' symptom status. Concordantly, we found the mean Ct-value to be lower for true positive (22.2 [95% CI 21.5 to 22.8]) compared to false negative (30.4 [95% CI 29.7 to 31.1]) results. Testing in the first week from symptom onset resulted in substantially higher sensitivity (81.9% [95% CI 77.7 to 85.5]) compared to testing after 1 week (51.8%, 95% CI 41.5 to 61.9). Similarly, sensitivity was higher in symptomatic

(76.2% [95% CI 73.3 to 78.9]) compared to asymptomatic (56.8% [95% CI 50.9 to 62.4]) persons. However, both effects were mainly driven by the Ct-value of the sample. With regards to sample type, highest sensitivity was found for nasopharyngeal (NP) and combined NP/oropharyngeal samples (70.8% [95% CI 68.3 to 73.2]), as well as in anterior nasal/mid-turbinate samples (77.3% [95% CI 73.0 to 81.0]).

Conclusion

Ag-RDTs detect most of the individuals infected with SARS-CoV-2, and almost all when high viral loads are present (>90%). With viral load, as estimated by Ct-value, being the most influential factor on their sensitivity, they are especially useful to detect persons with high viral load who are most likely to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, standardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms are needed.

INTRODUCTION

Antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 have proven to be a cornerstone in fighting the COVID-19 pandemic, as they provide results quickly and are easy to use [1]. Nevertheless, the Ag-RDTs' performance differs widely between manufacturers, the way they are performed, and the patients in which they are used [2, 3]. Thus, a comprehensive synthesis of evidence on commercially available Ag-RDTs and the factors influencing their accuracy is vital to guide public health decision makers in choosing the right test for their needs [4].

We previously conducted a living systematic review (available online at www.diagnosticsglobalhealth.org and updated weekly until August 31, 2021), summarizing the accuracy of commercially available Ag-RDTs reported in scientific literature. In an earlier analysis, including studies up until April 30, 2021, the pooled estimates of Ag-RDT sensitivity and specificity were 71.2% (95% confidence interval (CI) 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively, with the SARS-CoV-2 Antigen Test (LumiraDx, UK; henceforth called LumiraDx) being the most sensitive [4]. Since then, many additional studies have been published with a substantial increase in studies assessing asymptomatic participants, allowing for further sub-analysis of findings [3]. In prior studies, we and others found Ag-RDT sensitivity to decrease significantly in persons with lower viral load, as estimated by Ct-value, as well as asymptomatic persons or persons with more than 7 days since symptom onset (DOS > 7) [4]. However, studies including symptomatic patients enroll persons typically within days since onset of symptoms [5], when viral load is highest [6, 7]. On the contrary, studies including only asymptomatic persons have a higher chance of including persons at a later stage in the disease and thus with lower viral load. Therefore, the decrease in Ag-RDT sensitivity might only be driven by viral load, irrespective of persons' symptom status.

With the present work, we aim not only to give an updated overview on the accuracy of commercially available Ag-RDTs, but also to further explore the impact of viral load, the presence of symptoms and testing procedure on the accuracy of Ag-RDTs.

METHODS

We developed a study protocol following standard guidelines for systematic reviews [8, 9], which is available in the supplements (S1 Text). We also completed the PRISMA checklist (S1 PRISMA Checklist), and registered the review on PROSPERO (registration number: CRD42020225140).

Search strategy

We performed a search of the databases PubMed, Web of Science, medRxiv, and bioRxiv. The search terms were developed with an experienced medical librarian (M. Grilli), using combinations of subject headings (when applicable) and text-words for the concepts of the search question. The main search terms were "Severe Acute Respiratory Syndrome Corona-virus 2", "COVID-19", "Betacoronavirus", "Coronavirus", and "Point of Care Testing" with no language restrictions. The full list of search terms is available in S2 Text. We also manually searched the website of FIND, the global alliance for diagnostics (https://www.finddx.org/sarscov2-eval-antigen/), for additional relevant studies. We performed the search bi-weekly through August 31, 2021. The last manual search of the FIND website was performed on September 10, 2021. In addition to conducting the present review, we updated our website www.diagnosticsglobalhealth.org weekly with the latest search results based on the methods outlined below.

Inclusion criteria

We included studies evaluating the accuracy of commercially available Ag-RDTs to establish a diagnosis of SARS-CoV-2 infection at the point-of-care (POC), against reverse transcription polymerase chain reaction (RT-PCR) or cell culture as reference standard. We included all study populations irrespective of age, presence of symptoms or study location. We considered cohort studies, nested cohort studies, case–control or cross-sectional studies, and randomized studies. We included both peer-reviewed publications and preprints.

We excluded studies, in which patients were tested for the purpose of monitoring or ending quarantine. Also, publications with a population size smaller than 10 were excluded (although the size threshold of 10 is arbitrary, such small studies are more likely to give unreliable estimates of sensitivity and specificity). Analytical accuracy studies, where tests are performed on spiked samples with a known quantity of virus, were also excluded.

Index tests

Ag-RDTs for SARS-CoV-2 aim to detect infection by recognizing viral proteins (typically the SARS-CoV-2 nucleoprotein). Most Ag-RDTs dedicated for point-of-care deployment use specific labeled antibodies attached to a nitrocellulose matrix strip (lateral flow assay), to capture and detect the viral antigen. Successful binding of the antibodies to the antigen either is detected visually by the appearance of a line on the matrix strip or through a specific reader instrument for fluorescence detection. Other point-of-care instrument-based tests use chips or cartridges that enable an automated immunoassay testing procedure. Ag-RDTs typically provide results within 10 to 30 minutes [10].

Reference standard

Viral culture detects viable virus that is relevant for transmission but is only available in research settings. Since RT-PCR tests are more widely available and SARS-CoV-2 RNA (as reflected by RT-PCR cycle threshold [Ct] value) highly correlates with SARS-CoV-2 antigen quantities [11], we considered RT-PCR an acceptable reference standard for the purposes of this systematic review. Where an international standard for the correlation of the viral load to the Ct-values was used, we also report the viral load [12].

The study selection, data extraction, assessment of the quality of studies and their independence from manufacturers were performed as per prior description [4]. The data items extracted can be found in the Supplement (S1 Table).

145

146 Statistical analysis and data synthesis

147 We extracted raw data from the studies and recalculated performance estimates where possible
148 based on the extracted data. Also, some primary studies reported the median Ct-value along with the
149 first and third interquartile range (IQR) and/or minimum and maximum values rather than the sample
150 mean and standard deviation. To incorporate these studies in our analyses, we applied the Quantile
151 Estimation approach [13] to estimate the mean and standard deviation of the Ct-values. In an effort to
152 use as much of the heterogeneous data as possible, the cutoffs for the Ct value groups were relaxed
153 by 2–3 points within each range. The <20 group included values reported up to ≤20, the <25 group
154 included values reported as ≤24 or <25 or 20–25, and the <30 group included values from ≤29 to ≤33
155 and 25–30. The ≥25 group included values reported as ≥25 or 25 to 30, and the ≥30 group included
156 values from ≥30 to ≥35. For the same reason, when categorizing by age, the age group <18 years (chil-
157 dren) included samples from persons whose age was reported as <16 or <18 years, whereas the age
158 group ≥18 years (adults) included samples from persons whose age was reported as ≥16 or ≥18 years.
159 Also, for the symptom duration groups, the ≤7 days group included ≤4, ≤5, ≤6, 6 to 7, ≤7 and ≤9 days,
160 and the >7 days group >5, 6 to 10, 6-21, >7 and 8 to 14 days. The raw data can be found in the supple-
161 ments (S2 Table) and with more details online (https://doi.org/10.11588/data/T3MIB0). We prepared
162 forest plots for the sensitivity and specificity of each test and visually evaluated the heterogeneity
163 between studies.

164 If 4 or more datasets were available with at least 20 RT-PCR-positive samples per dataset for a
165 predefined analysis, a meta-analysis was performed. We report pooled estimates of sensitivity and
166 specificity for SARS-CoV-2 detection along with 95% confidence intervals (CIs) using a bivariate model
167 (implemented with the “reitsma” command from the R package “mada,” version 0.5.10). In subgroup
168 analyses (below), where papers presented data only on sensitivity, a univariate random effects inverse
169 variance meta-analysis was performed (using the “metagen” command from the R package “meta”,
170 version 5.1-1, and the “rma” command from the R package “metafor”, version 3.0-2). When there were

fewer than 4 studies for an index test, only a descriptive analysis was performed, and accuracy ranges are reported.

We predefined subgroups for meta-analysis based on the following characteristics: Ct value range, testing procedure in accordance with manufacturer's instructions as detailed in the instructions for use (IFU) (henceforth called IFU-conforming) versus not IFU-conforming, age (<18 versus ≥18 years), sample type, presence or absence of symptoms, symptom duration (<7 days versus ≥7 days), viral load, and type of RT-PCR assay used. We also provide mean Ct-value across true positive and false negative test results. For categorization by sample type, we assessed (1) nasopharyngeal (NP) alone or combined with other (e.g., oropharyngeal [OP]), (2) OP alone, (3) anterior nasal (AN) or mid-turbinate (MT), (4) a combination of bronchoalveolar lavage and throat wash (BAL/TW), or (5) saliva.

We applied multivariate linear mixed-effect meta-regression models to explore factors that affect diagnostic test sensitivity. Based on our previous analysis [4], we a priori defined an individual's time since infection and sample type and condition as underlying factors, influencing test sensitivity through an individual's symptom status (symptomatic vs. asymptomatic), the samples' viral load (estimated by the mean Ct-value as presented in the study for the sub cohort of interest) and the testing procedure (IFU- vs. not IFU-conforming). We performed 3 different analyses, each of which obtained unadjusted and adjusted estimates (i.e., an estimate of the association between a factor and test sensitivity, holding the other covariates in the model constant) of the effect of factors on test sensitivity.

In the first analysis, we estimated the direct effect of symptom status, viral load and testing procedure on test sensitivity. For the second and third analysis, we restricted the meta-regression models to data sets of symptomatic persons due to a lack of data. Specifically, the second analysis assessed the effect of time since infection (estimated as the sample mean of symptom duration), viral load, and testing procedure on test sensitivity. The third analysis also assessed the effect of time since infection, viral load, and testing procedure on test sensitivity, but depicted the time since infection as a binary covariate of the symptom duration subgroup (≤7 vs >7 days). Further details on the implementation of the meta-regression models and the underlying casual diagrams are available in the Supplement (S3

Text, S3a to S3c). Data sets with less than 5 RT-PCR positives were excluded. We considered an effect to be statistically significant when the regression coefficient's 95% confidence interval did not include 0. The analyses were performed using the "metafor" R package, version 3.0-2 [14].

As recommended to investigate publication bias for diagnostic test accuracy meta-analyses, we performed the Deeks test for funnel-plot asymmetry [15] (using the "midas" command in Stata, version 15); a p-value < 0.10 for the slope coefficient indicates significant asymmetry.

Sensitivity analysis

3 sensitivity analyses were performed: estimation of sensitivity and specificity excluding case–control studies, estimation of sensitivity and specificity excluding not peer-reviewed studies, and estimation of sensitivity and specificity excluding studies that were potentially influenced through test manufacturers. We compared the results of each sensitivity analysis against the overall results to assess the potential bias introduced by case–control, not peer-reviewed, and manufacturer-influenced studies.

RESULTS

SUMMARY OF STUDIES

The systematic search resulted in 31,254 articles. After removing duplicates, 11,462 articles were screened and 433 papers were considered eligible for full-text review. Of these, 259 were excluded because they did not present primary data or the Ag-RDT was not commercially available, leaving 174 studies to be included in the systematic review [16-189]. A list of the studies excluded and their reason for exclusion can be found in the Supplement (S4 Text). Further 20 studies were included from the FIND website [190-209] (Fig 1).



Fig 1: PRISMA flow diagram

Based on Page, M.J., et al. [210]. Abbreviations: Ag-RDT = antigen rapid diagnostic tests; IFU = instructions for use.

At the end of the data extraction process, 21 studies were still in preprint form [16, 17, 21, 47, 50, 55, 58, 65, 69, 74, 84, 100, 116, 121, 129, 160, 167, 168, 173, 174, 186]. All studies were written in English, except for 3 in Spanish [53, 62, 134], 1 in Turkish [95], and 1 in French [153]. Out of the 196 studies, 26 conducted a case-control study [21, 32, 34, 66, 67, 72, 81, 84, 88-90, 93, 94, 96, 103, 108, 135, 140, 144, 145, 151, 156, 166, 168, 182, 184], while the remaining 168 were cross-sectional or cohort studies. The reference method was RT-PCR in all except 1 study, which used viral culture [135].

The 194 studies were divided into 333 data sets. Across these, 76 different Ag-RDTs were evaluated (75 lateral flow assays, of which 63 are interpreted visually and 12 required an automated, proprietary reader; 1 assay is an automated immunoassay). The most common reasons for testing were

the occurrence of symptoms (98 data sets; 29.4% of data sets) and screening of asymptomatic persons with (3; 0.9%) or without (22; 6.6%) close contact to a SARS-CoV-2 confirmed case. In 142 (42.6%) of the data sets, individuals were tested due to more than 1 of the reasons mentioned and for 68 (20.4%) the reason for testing was unclear.

In total, 221,878 Ag-RDTs were performed, with a mean number of samples per study of 666 (Range 15 to 22,994). The age of the individuals tested was specified for only 90,986 samples, of which 84,124 (92.5%) were from adults (age group ≥18) and 6,862 (7.5%) from children (age group <18). Symptomatic persons comprised 74,118 (33.4%) samples, while 97,982 (44.2%) samples originated from asymptomatic persons, and for 49,778 (22.4%) samples the participant's symptom status was not stated by the authors. The most common sample type evaluated was NP and mixed NP/OP (117,187 samples, 52.8%), followed by AN/MT (86,354 samples, 38.9%). There was substantially less testing done on the other sample types, with 3,586 (1.6%) tests done from OP samples, 1,256 (0.6%) from saliva, 219 (0.1%) from BAL/TW and for 13,276 (6.0%) tests the type of sample was not specified in the respective studies.

A summary of the tests evaluated in clinical accuracy studies, including study author, sample size, sample type, sample condition, IFU conformity, and symptom status can be found in Supplement (S2 Table). The Standard Q test (SD Biosensor, South Korea; distributed in Europe by Roche, Germany; henceforth called Standard Q) was the most frequently used with 57 (17.1%) data sets and 36,246 (16.3%) tests, while the Panbio test (Abbott Rapid Diagnostics, Germany; henceforth called Panbio) was assessed in 55 (16.5%) data sets with 38,620 (17.4%) tests performed. Detailed results for each clinical accuracy study are available in the Supplement (S1 Fig).

METHODOLOGICAL QUALITY OF STUDIES

The findings on study quality using the QUADAS 2 tool are presented in Fig 2a and b. In 294 (88.3%) data sets a relevant study population was assessed. However, for only 68 (20.4%) of the data sets the selection of study participants was considered representative of the setting and population

261 chosen (i.e., they avoided inappropriate exclusions or a case-control design and enrollment occurred
262 consecutive or randomly).
263



264

265 **Fig 2a&b: (a)Methodological quality of the clinical accuracy studies (risk of bias) (b) Methodo-**
266 **logical quality of the clinical accuracy studies (applicability)**
267

268 The conduct and interpretation of the index tests was considered to have low risk of bias in 176
269 (52.9%) data sets (e.g., through appropriate blinding of persons interpreting the visual read-out). How-
270 ever, for 155 (46.5%) data sets sufficient information to clearly judge the risk of bias was not provided.
271 In only 151 (45.3%) data sets the Ag-RDTs were performed according to IFU, while 138 (41.4%) were
272 not IFU-conforming, potentially impacting the diagnostic accuracy; for 44 (13.2%) data sets the IFU
273 status was unclear. The most common deviations from the IFU were (1) use of samples that were pre-
274 diluted in transport media not recommended by the manufacturer (113 data sets; 12 unclear), (2) use
275 of banked samples (103 data sets; 12 unclear), and (3) a sample type that was not recommended for
276 Ag-RDTs (8 data sets; 11 unclear).
277 In 126 (37.8%) data sets the reference standard was performed before the Ag-RDT, or the opera-
278 tor conducting the reference standard was blinded to the Ag-RDT results, resulting in a low risk of bias.

In almost all other data sets (206; 61.9%) this risk could not be assessed, due to missing information and for 1 data set (0.3%) intermediate concern was raised. The applicability of the reference test was judged to be of low concern for all data sets, as viral culture or RT-PCR are considered to adequately define the target condition for the purpose of this study.

In 327 (98.2%) data sets, the sample for the index test and reference test were obtained at the same time, while this was unclear in 6 (1.8%). In 226 (67.9%) data sets, the same RT-PCR assay was used as the reference of all included samples, while in 85 (25.5%) data sets multiple RT-PCR assays were used as the reference. For 22 (6.6%) data sets, the RT-PCR used as reference standard was unclear. Furthermore, for 19 (5.7%) data sets, there was a concern that not all selected study participants were included in the analysis.

Finally, 45 (23.3%) of the studies received financial support from the Ag-RDT manufacturer. In 13 of these as well as in 2 others (in total 7.7% of all studies), employment of the authors by the manufacturer of the Ag-RDT studied was indicated. The respective studies are listed in the Supplement (S5 Text). Overall, a competing interest was found in 47 (24.2%) of the studies. Detailed assessment of each QUADAS domain can be found in the Supplement (S2 Fig).

DETECTION OF SARS-COV-2 INFECTION

Overall, 38 data sets were excluded from the meta-analysis, as they included fewer than 20 RT-PCR positive samples. An additional 28 data sets were missing either sensitivity or specificity and were only considered for univariate analyses. The remaining 267 data sets, evaluating 198,584 tests, provided sufficient data for bivariate analysis. The results are presented in Fig 3a-e. Detailed results for the subgroup analysis are available in the Supplement (S3 Fig, S4 Fig, S5 Fig, S6 Fig and S7 Fig).

Including any test and type of sample, the pooled estimates of sensitivity and specificity were 72.0% (95%CI 69.8 to 74.2) and 98.9% (95%CI 98.6 to 99.1), respectively. If testing was performed according to IFU, sensitivity increased to 76.4% (95%CI 73.8 to 78.8) compared to not IFU-conforming

304 testing with a sensitivity of 66.7% (95%CI 62.6 to 70.6). Pooled specificity was similar in both groups:
305 99.1% (95% CI 98.8-99.3) and 98.4% (95% CI 97.8 to 98.8), respectively (Fig 3a).
306
307 **Subgroup analysis by Ct-value**
308 In samples with Ct-values <20 a very high estimate of sensitivity was found (97.9% [95% CI 96.9
309 to 98.9]). The pooled sensitivity for Ct-values <25 was markedly better at 90.6% (95% CI 88.3 to 93.0)
310 compared to the group with Ct ≥ 25 at 54.4% (95% CI 47.3 to 61.5). A similar pattern was observed
311 when the Ct-values were analyzed using cut-offs <30 or ≥30, resulting in an estimated sensitivity of
312 76.8% (95% CI 73.1 to 80.4) and 18.7% (95% CI 13.9 to 23.4), respectively (Fig 3b).
313 When pooling Ct-value estimates for true positive (TP) Ag-RDT results (TP; 5,083 samples; 69 data
314 sets) and false negative (FN) (2,408 samples; 78 data sets) Ag-RDT results, the mean Ct-values were
315 22.2 (95% CI 21.5 to 22.8) and 30.4 (95% CI 29.7 to 31.1), respectively (S8 Fig). Across both TP and FN
316 samples, mean Ct-value was 26.3 (95% CI 25.5 to 27.1). This demonstrates that RT-PCR positive sam-
317 ples missed by Ag-RDT have a substantially lower viral load (higher Ct-value) compared to those that
318 were detected. Individual forest plots for each data set with mean Ct-values are presented in the Sup-
319 plement (S9 Fig).
320
321 **Subgroup analysis by sample type**
322 Most data sets evaluated NP or combined NP/OP swabs (197 data sets and 104,341 samples) as
323 the sample type for the Ag-RDT. NP or combined NP/OP swabs achieved a pooled sensitivity of 70.8%
324 (95% CI 68.3 to 73.2) and specificity of 98.8% (95% CI 98.6 to 99.1). Data sets that used AN/MT swabs
325 for Ag-RDTs (52 data sets and 84,020 samples) showed a summary estimate for sensitivity of 77.3%
326 (95% CI 73.0 to 81.0) and specificity of 99.1% (95% CI 98.6 to 99.4). However, 2 studies that reported
327 direct head-to-head comparison of NP and AN/MT samples from the same participants using the same
328 Ag-RDT (Standard Q) reported equivalent performance [112, 113]. In contrast, saliva swabs (4 data
329 sets, 1,216 samples) showed the lowest pooled sensitivity with only 50.1% (95% CI 7.7 to 92.3) (Fig 3c).

In 3 of the data sets utilizing a saliva sample, saliva was collected as whole mouth fluid [20, 88, 150]. The fourth used a cheek swab for sample collection [51].

Due to only 3 data sets with 3586 samples, we were not able to estimate pooed sensitivity and specificity for OP samples. Median sensitivity and specificity were 59.4% (range 50.0% to 81.0%) and 99.1% (range 99.0% to 100.0%), respectively. We were also not able to perform a subgroup meta-analysis for BAL/TW due to insufficient data, with only 1 study with 73 samples evaluating the Biocredit Covid-19 Antigen rapid test kit (RapiGEN, South Korea; henceforth called Rapigen), Panbio and Standard Q available and sensitivity ranging between 33.3% and 88.1% [151]. However, the use of BAL/TW sampling would be considered not IFU-conforming.

Subgroup analysis in symptomatic and asymptomatic participants

Within the data sets possible to meta-analyze, 55,186 (43.2%) samples were from symptomatic and 72,457 (56.8%) from asymptomatic persons. The pooled sensitivity for symptomatic persons was markedly higher compared to asymptomatic persons with 76.2% (95% CI 73.3 to 78.9) vs. 56.8% (95% CI 50.9 to 62.4). Specificity was above 98.6% for both groups (Fig 3d).

Subgroup analysis comparing symptom duration

Data were analyzed for 9,470 persons from 26 data sets with symptoms less than 7 days, while for persons with symptoms $\geq$ 7 days fewer data were available (620 persons, 13 data sets). The pooled sensitivity estimate for individuals with symptoms <7 days was 81.9% (95% CI 77.7 to 85.5), which is markedly higher than the 51.8% (95% CI 41.5 to 61.9) sensitivity for individuals tested $\geq$ 7 days from onset of symptoms (Fig 3d).

Subgroup analysis by age

For adults (age group ≥18), it was possible to pool estimates across 62,433 samples, whereas the pediatric group (age group <18) included 5,137 samples. There was only a small difference with

356 overlapping confidence intervals in sensitivity with 74.8% (95% CI 71.5 to 77.8) and 69.8% (95% CI 61.0
357 to 77.3) for the adult and pediatric group, respectively. For those data sets that reported a median Ct-
358 value per age group, the Ct-value was slightly lower in the adult (median 22.6; Q1 = 20.5; Q3 = 24.6;
359 48 data sets) compared to the pediatric group (median 23.2; Q1 = 20.3; Q3 = 25.2; 3 data sets). Speci-
360 ficity was similar in both groups with over 99% (Fig 3e).

361

Testing procedure	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
IFU	126	108718	76.4% (73.8–78.8)	99.1% (98.8–99.3)
non–IFU	107	45319	66.7% (62.6–70.6)	98.4% (97.8–98.8)
unclear	34	44547	71% (64.8–76.6)	99.2% (98.7–99.5)

Fig. a



Ct Values	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)
<20	60	2200	97.9% (96.9–98.9)
>=20	36	1850	85.9% (80–91.8)
<25	132	12791	90.6% (88.3–93)
>=25	59	2509	54.4% (47.3–61.5)
<30	139	15951	76.8% (73.1–80.4)
>=30	62	1714	18.7% (13.9–23.4)

Fig. b



Sample type	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
AN/MT	52	84020	77.3% (73–81)	99.1% (98.6–99.4)
NP	197	104341	70.8% (68.3–73.2)	98.8% (98.6–99.1)
saliva	4	1216	50.1% (7.7–92.3)	99% (96.4–99.7)
unclear	9	5276	78.1% (63–88.2)	99.2% (97.9–99.7)

Fig. c



Symptoms	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
Asymptomatic	57	72457	56.8% (50.9–62.4)	99.1% (98.7–99.4)
Symptomatic	110	55186	76.2% (73.3–78.9)	98.6% (98.1–98.9)
Symptoms <7 days	26	9470	81.9% (77.7–85.5)	98.6% (97.8–99.1)
Symptoms >=7 days	13	620	51.8% (41.5–61.9)	95.9% (92.5–97.8)

Fig. d



Age group	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
Age <18 years	10	5137	69.8% (61–77.3)	99.2% (98.1–99.7)
Age >=18 years	102	62433	74.8% (71.5–77.8)	99.1% (98.8–99.3)

Fig. e



362

Fig 3a-e: Pooled sensitivity and specificity by IFU conformity, Ct-value*, sample type, symptom status, duration of symptoms and age

*Low Ct-values are the RT-PCR semi-quantitative correlate for a high virus concentration. Abbreviations: N = number of, CI = confidence interval, IFU = instructions for use, NP = nasopharyngeal, AN = anterior nasal, MT = mid turbinate, *only sensitivity calculated

META REGRESSION

The first analysis, assessing all variables that could influence sensitivity (symptom status, testing procedure [IFU-conforming vs. not IFU-conforming], and mean Ct-value), included 65 data sets of symptomatic and 18 of asymptomatic persons. The second and third analysis assessed only symptomatic persons with 28 and 50 data sets, respectively. The full list of data sets for each analysis and detailed results are available in the Supplement (S3 Text).

In the first analysis, we found viral load (as estimated by Ct-value) to be the driving factor of sensitivity. Sensitivity was estimated to increase by 2.9 percentage points (95% CI 1.7 to 4.0) for every unit the mean Ct-value decreased (Fig 4, Supplement Text S3d), after adjusting for symptom status and testing procedure. In addition, sensitivity was estimated to be 20.0 percentage points (95% CI 13.7 to 26.3) higher for samples from symptomatic compared to asymptomatic participants. However, when controlling for testing procedure and mean Ct-value, this difference declined to only 11.1 percentage points (95% CI 4.8 to 17.4). The difference between IFU-conforming vs. not IFU-conforming testing procedure was not significant (5.2 percentage points [95% CI -2.6 to 13.0] higher for IFU-conforming) after controlling for symptom status and mean Ct-value.



Fig 4: Pooled estimate of sensitivity across mean Ct-values holding symptom status and IFU-status constant at their respective means

Dotted lines are the corresponding 95% confidence intervals. The size of each point is a function of the weight of the data set in the model, where larger data sets have larger points. Abbreviations: Ct = cycle threshold

When assessing only symptomatic participants, test sensitivity was estimated to decrease by 3.2 percentage points (95% CI -1.5 to 7.9) for every 1 day increase in average duration of symptoms (mean duration of symptoms ranged from 2.75 to 6.47 days). However, with the confidence interval including the value zero, this effect was not statistically significant. When controlling for mean Ct-value and testing procedure, the estimated effect of the average duration of symptoms was close to 0 (0.7 percentage points [95% CI -5.0 to 6.4], Supplement Text S3e).

Concordantly, for samples collected after 7 days of symptom onset sensitivity was estimated to be 22.9 percentage points [95%CI 10.3 to 35.4] lower compared to those collected within 7 days. When controlling for mean Ct-value and testing procedure, the model still showed a decrease in sensitivity

for samples collected after 7 days of symptom onset, but again closer to zero and no longer statistically significant (-13.8 percentage points [95% CI -27.7 to 0.1], Supplement Text S3f).

ANALYSIS OF INDIVIDUAL TESTS

Based on 179 data sets with 143,803 tests performed, we were able to perform bivariate meta-analysis of the sensitivity and specificity for 12 different Ag-RDTs (Fig 5). Across these, pooled estimates of sensitivity and specificity on all samples were 71.6% (95%CI 69.0 to 74.1) and 99.0% (95% CI 98.8 to 99.2), which were very similar to the overall pooled estimate across all meta-analyzed data sets (72.0% and 98.9%, above).

Test assessed	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
BD Veritor	7	5721	71.2% (56.8–82.3)	99.2% (98.6–99.6)
BinaxNow	11	31104	68.5% (54.3–79.9)	99.4% (98.2–99.8)
CLINITEST	4	1006	75.2% (49.8–90.3)	98.7% (97.2–99.4)
Coris	7	1882	48.4% (36.1–61)	99.1% (98.1–99.6)
Innova	4	7218	72.2% (47.1–88.4)	99.3% (94.1–99.9)
LumiraDx	11	4772	82.7% (73.2–89.4)	96.9% (94.4–98.3)
Panbio	48	32370	71.9% (66.8–76.4)	99.5% (99.2–99.7)
Rapigen	6	2116	62% (46.7–75.2)	98.5% (94–99.6)
Sofia	11	9739	76.4% (70.9–81.2)	99% (98.3–99.4)
Standard F	11	9259	66.4% (57.3–74.4)	97.9% (96.9–98.5)
Standard Q	51	35664	70.9% (65.9–75.5)	98.8% (98.2–99.2)
Standard Q nasal	8	2952	81.4% (73.8–87.2)	99.1% (98.4–99.5)



Fig 5: Bivariate analysis of 12 Ag-RDTs

Pooled sensitivity and specificity were calculated based on reported sample size, true positives, true negatives, false positives, and false negatives. Abbreviations: N = number of, CI = confidence interval

The highest pooled sensitivity was found for the SARS-CoV-2 Antigen Test (LumiraDx, United Kingdom; henceforth called LumiraDx) and the Standard Q nasal test (SD Biosensor, South Korea;

distributed in Europe by Roche, Germany; henceforth called Standard Q nasal) with 82.7% (95% CI 73.2 to 89.4) and 81.4% (95% CI 73.8 to 87.2), respectively. However, all tests except the COVID-19 Ag Respi-Strip (Coris BioConcept, Belgium; henceforth called Coris; sensitivity 48.4% (95% CI 36.1 to 61.0) had confidence intervals that were overlapping. The pooled specificity was above 98% for all of the tests, except for the Standard F test (SD Biosensor, South Korea; henceforth called Standard F) and LumiraDx with specificities of 97.9% (95% CI 96.9 to 98.5) and 96.9% (95% CI 94.4 to 98.3), respectively. Hierarchical summary receiver-operating characteristic for LumiraDx and Standard Q nasal are available in the Supplement (S10 Fig).

For 2 Ag-RDTs, we were only able to perform a univariate analysis, due to insufficient data. Sensitivities for the COVID-19 Rapid Antigen Test Cassette (SureScreen, United Kingdom; henceforth called SureScreen V) and the Nadal COVID-19 Ag Test (Nal von Minden, Germany; henceforth called Nadal) were similar with 57.7% (95% CI 40.9 to 74.4) and 56.6% (95% CI 26.9 to 86.3), respectively (Fig S11). Specificity was only possible to calculate for the Nadal, which was lowest throughout the per test analysis with 91.1% (95% CI 80.2 to 100). For the remaining 62 Ag-RDTs, there were insufficient numbers of data sets for a uni-or bivariate meta-analysis, but performance estimates for each of these tests are descriptively compared in the Supplement (S3 Table).

For Panbio and Standard Q, it was also possible to pool sensitivity per Ct-value subgroup for each individual test. Panbio and Standard Q reached sensitivities of 97.2% (95% CI 95.3 to 99.2) and 98.1% (95% CI 96.3 to 99.9) for Ct-value <20, 89.8% (95% CI 85.4 to 94.3) and 92.6% (95% CI 88.5 to 96.7) for Ct-value <25 and 73.7% (95% CI 66.0 to 81.3) and 75.7% (95% CI 67.9 to 83.4) for Ct-value <30, respectively. For Ct-value ≥20 sensitivities for Panbio and Standard Q were 89.2% (95% CI 82.1 to 96.3) and 89.0% (95% CI 81.0 to 96.9), 51.3% (95% CI 32.9 to 69.7) and 57.0% (95% CI 36.9 to 77.0) for Ct-value ≥25, and 22.8% (95% CI 11.3 to 34.3) and 23.7% (95% CI 13.6 to 33.8) for Ct-value ≥30, respectively (S4 Fig A-F). For BinaxNow (Abbott Rapid Diagnostics, Germany), LumiraDx, SD Biosensor, Standard F, Coris and INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test (Innova Medical Group, USA; henceforth called Innova) sufficient data to pool sensitivity was only available for certain Ct-values, which are

445 available in the Supplement (S4 Fig A-F) as well. In addition, for 8 tests it was possible to calculate
446 pooled sensitivity and specificity estimates only including data sets that conformed to the IFU. These
447 are also listed in the Supplement (S4 Table).

448 In total, 31 studies accounting for 106 data sets conducted head-to-head clinical accuracy evalu-
449 ations of different tests using the same sample(s) from the same participant. These data sets are out-
450 lined in the Supplement (S2 Table). 9 studies performed their head-to-head evaluation as per IFU and
451 on symptomatic individuals. Across 4 studies, the Standard Q nasal (sensitivity 80.5% to 91.2%) and
452 the Standard Q (sensitivity 73.2% to 91.2%) showed a similar range of sensitivity [112, 126, 211]. 1
453 study reported a sensitivity of 60.4% (95% CI 54.9 to 65.6) for the Standard Q and 56.8% (95% CI 51.3
454 to 62.2) for the Panbio in a mixed study population of symptomatic, asymptomatic and high-risk con-
455 tact persons [186]. Another study described a sensitivity of 56.4% (95% CI 44.7 to 67.6) for the Rapigen
456 and 52.6% (95% CI 40.9 to 64) for the SGTi-flex COVID-19 Ag (Sugentech, South Korea) [160]. 1 study
457 included only very few samples and using a not IFU-conforming sample type (BAL), limiting the ability
458 to draw conclusions from the results [151].

459

460 SENSITIVITY ANALYSIS

461 We performed 3 sensitivity analyses including 213 data sets for non-case-control studies, 216
462 data sets including only peer reviewed studies and 190 data sets including only data sets without any
463 manufacturer influence. When excluding case-control studies, the sensitivity and specificity remained
464 at 71.9% (95% CI 69.4 to 74.2) and 99.0% (95% CI 98.8 to 99.2), respectively. Similar, when assessing
465 only peer reviewed studies sensitivity and specificity did not change significantly with 71.1% (95% CI
466 68.5 to 73.6) and 98.9% (95% CI 98.6 to 99.1), respectively. If studies that could have potentially been
467 influenced by test manufacturers were excluded, sensitivity decreased marginally, but with overlap-
468 ping confidence intervals (sensitivity of 70.3% [95% CI 67.6 to 72.9] and specificity of 99.0% [95% CI
469 98.7 to 99.2]).

470

DISCUSSION

After reviewing 194 clinical accuracy studies, we found Ag-RDTs to be 76.4% (95%CI 73.8 to 78.8) sensitive and 99.1% (95% CI 98.8 to 99.3) specific in detecting SARS-CoV-2 compared to RT-PCR when performed according to manufacturers' instructions. Viral load as estimated by Ct-value was the deciding factor for sensitivity, confirming prior work [11]. There was a significant correlation between test sensitivity and Ct-value, with sensitivity increasing by 2.9 percentage points for every unit decrease in mean Ct-value when controlling for symptom status and testing procedure. The pooled Ct-value for TP was on average over 8 points lower than for FN results (Ct-value of 22.2 for TP compared to 30.4 for FN results). A decrease in performance when not following manufacturer's instructions was suggested but was not significant (-5.2 percentage points [95% CI -13.0 to 2.6]).

Furthermore, sensitivity was found to be higher when samples were from symptomatic (76.2% sensitivity) compared to asymptomatic participants (56.8% sensitivity). This was confirmed in the regression model, estimating sensitivity to be 20.0 percentage points higher in samples that originated from symptomatic participants. In our previous analysis, we assumed that the increase in sensitivity is not due to the symptom status as such, but results from the fact that in symptomatic study populations chances are higher to include participants at the beginning of the disease with high viral load [4]. In the present analysis, this assumption shows to be largely true. Controlling for Ct-value, the RT-PCR correlate for viral load, the effect of symptomatic vs. asymptomatic participants on test sensitivity strongly decreased to 11.1 percentage points. As others found symptomatic and asymptomatic individuals to have the same viral load when at the same stage of the disease [6], we would have expected the regression coefficient to have decreased even further to 0. This non-zero difference in sensitivity between symptomatic and asymptomatic participants may be due to the lack of access to individual participant Ct-values, which required our analyses to control for the mean Ct-value over all participants in a data set rather than the individual Ct-values. Furthermore, some variability is likely introduced by the testing for the Ag-RDT and the RT-PCR not to occur from the sample. Therefore, some degree of residual confounding is likely present.

We also found sensitivity to be higher when participants were tested within 7 days of symptom onset (81.9% sensitivity) compared to > 7 days (51.8% sensitivity). Concordantly, our regression model estimated that sensitivity decreases by 3.2 percentage points for every 1 day increase in mean symptom duration. Again, this decrease in sensitivity is driven by viral load as was seen when controlling for Ct-value. Importantly, it is not yet clear how the emergence of new SARS-CoV-2 variants of concern and the growing vaccination coverage will affect Ag-RDTs sensitivity in the early days after symptom onset. Most of the studies included in this analysis were performed at the time the wildtype and Alpha variant were circulating. While data confirmed similar Ag-RDT sensitivity in the Delta variant compared to wildtype, for the Omicron SARS-CoV-2 variant the first data in analytical studies suggests similar and possibly lower performance [212, 213]. Vaccination did not affect viral kinetics in the first week [214] and is unlikely to do so for the Omicron variant [215]. To further inform public health decision makers on the best strategy to apply Ag-RDTs, clinical accuracy studies in settings with high prevalence of the Omicron variant are urgently needed.

Looking at specific tests, LumiraDx and Standard Q nasal showed the highest sensitivity, performing above the 80% sensitivity target defined by the World Health Organization. However, while the Standard Q nasal was 99.1% (95% CI 98.4 to 99.5) specific, the LumiraDx only had a specificity of 96.9% (95% CI 94.4-98.3), which is just below the WHO target of 97%. The reason for the lower specificity is unclear, particularly as independent analytical studies also confirmed the test had no cross-reactivity [102]. Sample to sample variability must be considered, particularly as the sensitivity of the index tests approaches that of the reference test. The 2 most often evaluated tests, namely Panbio (32,370 samples; sensitivity of 71.9%) and Standard Q (35,664 samples; sensitivity of 70.9%), performed slightly below the overall average. Similarly, Panbio and Standard Q were also the most extensively evaluated Ag-RDTs in the prior analysis, and with a sensitivity slightly above average [4]. Nonetheless, this updated analysis indicates that there is limited added value is to be expected from any further analysis of Ag-RDTs' overall sensitivity or the sensitivity of the most widely-evaluated tests. However, it will be important to continue to reassess tests' analytical sensitivity for detection of new specific variants

(e.g., Omicron). Also, it would be of interest to evaluate the characteristics of specific formats of Ag-RDTs, such as Ag-RDTs that are self-performed or those that are instrument-based.

Furthermore, sensitivity strongly differed between studies that conducted the Ag-RDTs as per manufacturer's instructions and those that did not (sensitivity of 66.7% for not IFU-conforming vs. 76.4% for IFU-conforming). With regards to sample types, saliva showed a markedly lower sensitivity of 50.1%, compared to NP or AN/MT samples, confirming what we found in our previous analysis [4]. Especially in light of the current debate on whether saliva or throat swabs might be a more sensitive sample to detect the SARS-CoV-2 Omicron variant than NP or AN/MT samples [216-218], further research is urgently needed to quantify the difference in viral load resulting from different sample types and thus the effect of sample type on test sensitivity.

In concordance with the above, many studies reporting an unusually low sensitivity performed the Ag-RDT not as per IFU [26, 28, 40, 66, 97, 108, 133, 184] or used saliva samples [20, 150, 155, 219]. However, 2 studies with IFU-conforming testing procedure on NP or AN/MT sample, still showed a low sensitivity. This quite likely results from the on average low viral load in 1 study [49], and the asymptomatic study population in the other [175]. On the contrary, compared to the other studies unusual high sensitivity was found in studies where average viral load was high [45, 84, 144, 145] or participants were mainly within the first week of symptom onset [42, 54, 135].

The main strength of our study lies in its living approach. The ability to update our methodology as the body of evidence grows has enabled more improved analysis. For example, while data were too heterogenous for a meta-regression during the prior analysis, with additional datasets we are now able to analyze the relationship between an Ag-RDT's sensitivity, the samples' Ct-value, and the participants' symptom status in depth. Similarly, we decided to focus on clinical accuracy studies for POC Ag-RDTs in this current review as analytical accuracy studies require a dedicated approach to be comparable. Furthermore, the main results of our latest extractions are publicly available on our website. This has not only equipped public health professionals with an up-to-date overview on the current

research landscape [220, 221], but also led other researchers and the test manufacturers to check our data, improving the quality of our report through continuous peer-review.

Nonetheless, our study is limited in that we use RT-PCR as a reference standard to assess the accuracy of Ag-RDTs, which might be a less appropriate reference standard than viral culture [135, 222]. However, viral culture is available in research settings only and its validity as a true proxy of actual transmissibility is not proven, therefore we find RT-PCR a suitable reference standard for the clinical accuracy studies included in this review. Furthermore, we fully acknowledge that Ct-value is not equivalent to viral load, and that the correlation between Ct-value and viral load varies between RT-PCR assays; nonetheless, we believe that the analysis of pooled Ct-value data across a very large data set is a useful strategy to understand the overall contribution of viral load to Ag-RDT performance. Finally, we are aware that the test specific sensitivities and specificities can be influenced by differences in study design. However, we aimed to counterbalance this effect by assessing relevant aspects in study design for each study and analyzing outliers. To enhance comparability in between clinical accuracy studies, future studies should include individuals at a similar stage in the disease, use the same sample types and adhere to the WHO standard for measuring SARS-CoV-2 viral load [12].

CONCLUSION

In summary, Ag-RDTs detect most of the persons infected with SARS-CoV-2 when performed according to the manufacturers' instructions. While this confirms the results of our previous analysis, the present analysis highlights that the sample's viral load is the most influential factor underlying test sensitivity. Thus, Ag-RDTs can play a vital role in detecting persons with high viral load and therefore likely to be at highest risk of transmitting the virus. This holds true even in the absence of patient symptoms or differences in the duration of symptoms. To foster further research analyzing specific Ag-RDTs and the factors influencing their sensitivity in more detail, standardization of clinical accuracy studies and access to patient level Ct-value and duration of symptoms are essential.

REFERENCES

1. World Health Organization, *Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities.* No. WHO/publications/i/item/WHO-2019-nCoV-lab-testing-2021.1-eng, 2021.
2. Dinnes, J., et al., *Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.* Cochrane Database of Systematic Reviews, 2021. **3**: p. CD013705.
3. World Health Organization, *Antigen-detection in the diagnosis of SARS-CoV-2 infection.* WHO Reference Number: WHO/2019-nCoV/Antigen_Detection/2021.1, 2021.
4. Brümmer, L.E., et al., *Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis.* PLoS Medicine, 2021. **18**(8): p. e1003735.
5. Nehme, M., et al., *COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings.* Ann Intern Med, 2021. **174**(5): p. 723-725.
6. Kissler, S.M., et al., *Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies.* PLoS Biol, 2021. **19**(7): p. e3001333.
7. Wang, Y., et al., *Kinetics of viral load and antibody response in relation to COVID-19 severity.* J Clin Invest, 2020. **130**(10): p. 5235-5244.
8. Leeflang, M.M., et al., *Systematic reviews of diagnostic test accuracy.* Annals of Internal Medicine, 2008. **149**(12): p. 889-97.
9. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.* Annals of Internal Medicine, 2009. **151**(4): p. 264-9, W64.
10. World Health Organization, *Antigen-detection in the diagnosis of SARS-CoV-2 infection: interim guidance, 6 October 2021.* WHO/2019-nCoV/Antigen_Detection/2021.1, 2021.
11. Pollock, N., et al., *Correlation of SARS-CoV-2 Nucleocapsid Antigen and RNA Concentrations in Nasopharyngeal Samples from Children and Adults Using an Ultrasensitive and Quantitative Antigen Assay.* Journal of Clinical Microbiology, 2020. **59**: p. e03077-20.
12. World Health Organization, *First WHO International Standard for SARS-CoV-2 RNA.* Version 3.0, Dated 11/02/2021, 2021.
13. McGrath, S., et al., *Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis.* Stat Methods Med Res, 2020: p. 962280219889080.
14. Viechtbauer, W., *Conducting Meta-Analyses in R with the metafor Package.* Journal of Statistical Software, 2010. **36**(3): p. 1–48.
15. van Enst, W.A., et al., *Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study.* BMC Med Research Methodology, 2014. **14**: p. 70.
16. Abdul-Mumin, A., et al., *Field evaluation of specificity and sensitivity of a standard SARS-CoV-2 antigen rapid diagnostic test: A prospective study at a teaching hospital in Northern Ghana.* medRxiv [Preprint]; published September 17, 2021.
17. Abdulrahman, A., et al., *Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients.* medRxiv [Preprint]; published December 08, 2020.
18. Abusrewil, Z., et al., *Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays.* Journal of Medical Virology, 2021: p. 1-7.
19. Agarwal, J., et al., *"David vs. Goliath": A simple antigen detection test with potential to change diagnostic strategy for SARS-CoV-2.* Journal of Infection in Developing Countries, 2021. **15**(7): p. 904-909.
20. Agulló, V., et al., *Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs: A population-based point-of-care study.* Journal of Infection, 2020. **82**(5): p. 186-230.
21. Akashi, Y., et al., *Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2.* medRxiv [Preprint]; published June 13, 2021.
22. Akingba, O.L., K. Sprong, and D.R. Hardie, *Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South Africa.* Journal of Clinical Virology Plus, 2021. **1**(1-2): p. 100013.

23. Albert, E., et al., *Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.* Clinical Microbiology and Infection, 2020. **27**(3): p. 472.e7–472.e10.
24. Alemany, A., et al., *Analytical and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test.* Journal of Infection, 2020. **82**(5): p. 186-230.
25. Allan-Blitz, L.T. and J.D. Klausner, *A Real-World Comparison of SARS-CoV-2 Rapid Antigen vs. Polymerase Chain Reaction Testing in Florida.* Journal of Clinical Microbiology, 2021. **59**(10): p. e0110721.
26. Baccani, I., et al., *Evaluation of Three Immunoassays for the Rapid Detection of SARS-CoV-2 Antigens.* Diagnostic Microbiology and Infectious Disease, 2021. **101**(2): p. 115434.
27. Bachman, C.M., et al., *Clinical validation of an open-access SARS-COV-2 antigen detection lateral flow assay, compared to commercially available assays.* PLoS One, 2021. **16**(8): p. e0256352.
28. Baro, B., et al., *Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison.* Journal of Infection, 2021. **82**(6): p. 269-275.
29. Beck, E.T., et al., *Comparison of Quidel Sofia SARS FIA Test to Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients.* Journal of Clinical Microbiology, 2020. **59**(2): p. e02727-20.
30. Berger, A., et al., *Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers.* PLoS ONE, 2020. **16**(3): p. e0248921.
31. Bianco, G., et al., *Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection.* Journal of Clinical Virology, 2021. **139**: p. 104838.
32. Blairon, L., et al., *Efficacy comparison of three rapid antigen tests for SARS-CoV-2 and how viral load impact their performance.* Journal of Medical Virology, 2021. **93**: p. 5783-5788.
33. Bornemann, L., et al., *Real-life evaluation of the Sofia SARS-CoV-2 antigen assay in a large tertiary care hospital.* Journal of Clinical Virology, 2021. **140**: p. 104854.
34. Bouassa, M.R.S., et al., *Analytical performances of the point-of-care SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: A prospective evaluation during the COVID-19 second wave in France.* International Journal of Infectious Diseases, 2021. **106**: p. 8-12.
35. Brihn, A., et al., *Diagnostic Performance of an Antigen Test with RT-PCR for the Detection of SARS-CoV-2 in a Hospital Setting - Los Angeles County, California, June-August 2020.* Morbidity and Mortality Weekly Report, 2021. **70**(19): p. 702-706.
36. Bruzzone, B., et al., *Comparative diagnostic performance of different rapid antigen detection tests for COVID-19 in the real-world hospital setting.* International Journal of Infectious Diseases, 2021. **107**: p. 215-218.
37. Bulilete, O., et al., *Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care.* Journal of Infection, 2021. **82**: p. 391-398.
38. Caramello, V., et al., *Are antigenic tests useful for detecting SARS-CoV-2 infections in patients accessing to emergency departments? Results from a North-West Italy Hospital.* Journal of Infection, 2021. **83**: p. 237-279.
39. Carbonell-Sahuquillo, S., et al., *Evaluation of a rapid antigen detection test (Panbio™ COVID-19 Ag Rapid Test Device) as a point-of-care diagnostic tool for COVID-19 in a Pediatric Emergency Department.* Journal of Medical Virology, 2021: p. 1-5.
40. Caruana, G., et al., *ImplemeNting SARS-CoV-2 Rapid antigen testing in the Emergency wArd of a Swiss univErsity hospital: the INCREASE study.* microorganisms, 2021. **9**(4): p. 798.
41. Caruana, G., et al., *The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients.* New Microbes and New Infections, 2021. **42**: p. 100899.
42. Cassuto, N.G., et al., *Evaluation of a SARS-CoV-2 antigen-detecting rapid diagnostic test as a self-test: diagnostic performance and usability.* Journal of Medical Virology, 2021: p. 1-7.

43. Cento, V., et al., *Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR?* Viruses-Basel, 2021. **13**(5): p. 818.
44. Cerutti, F., et al., *Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2.* Journal of Clinical Virology, 2020. **132**: p. 104654.
45. Chaimayo, C., et al., *Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand.* Virology Journal, 2020. **17**(1): p. 177.
46. Chiu, R., et al., *Evaluation of the INDICAID COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing.* Microbiology Spectrum, 2021. **9**(1): p. e0034221.
47. Christensen, K., et al., *Clinical evaluation of BD Veritor™ SARS-CoV-2 and Flu A+B Assay for point-of-care (POC) System.* medRxiv [Preprint]; published May 05, 2021.
48. Ciotti, M., et al., *Performance of a rapid antigen test in the diagnosis of SARS-CoV-2 infection.* Journal of Medical Virology, 2021. **93**: p. 2988–2991.
49. Dankova, Z., et al., *Comparison of SARS-CoV-2 Detection by Rapid Antigen and by Three Commercial RT-qPCR Tests: A Study from Martin University Hospital in Slovakia.* International Journal of Environmental Research and Public Health, 2021. **18**(13).
50. Del Vecchio, C., et al., *Emergence of N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests.* medRxiv [Preprint]; published March 26, 2021.
51. Di Domenico, M., et al., *Diagnostic Accuracy of a New Antigen Test for SARS-CoV-2 Detection.* International Journal of Environmental Research and Public Health, 2021. **18**(12): p. 6310.
52. Dierks, S., et al., *Diagnosing SARS-CoV-2 with Antigen Testing, Transcription-Mediated Amplification and Real-Time PCR.* Journal of Clinical Medicine, 2021. **10**(11): p. 2404.
53. Domínguez Fernández, M., et al., *Experience with Panbio rapid antigens test device for the detection of SARS-CoV-2 in nursing homes.* Enfermedades Infecciosas y Microbiología Clínica, 2021. **S0213-005X**.
54. Drain, P.K., et al., *A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study.* Infectious Diseases and Therapy, 2021. **10**(2): p. 753–761.
55. Drevinek, P., et al., *The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing.* medRxiv [Preprint]; published November 24, 2020.
56. Eleftheriou, I., et al., *Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children.* Journal of Medical Virology, 2021.
57. Escrivá, B.F., et al., *The effectiveness of rapid antigen test-based for SARS-CoV-2 detection in nursing homes in Valencia, Spain.* Journal of Clinical Virology, 2021. **143**: p. 104941.
58. Faíco-Filho, K.S., et al., *Evaluation of the Panbio™ COVID-19 Ag Rapid Test at an Emergency Room in a Hospital in São Paulo, Brazil.* medRxiv [Preprint]; published March 24, 2021.
59. Favresse, J., et al., *Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection.* Journal of Clinical Medicine, 2021. **10**(2): p. 265.
60. Fenollar, F., et al., *Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19.* Journal of Clinical Microbiology, 2020. **59**: p. e02589-20.
61. Ferguson, J., et al., *Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing frequency and public health messaging is key.* PLoS Biol, 2021. **19**(4): p. e3001216.
62. Fernández, M.D., et al., *Usefulness of the LumiraDx SARS-COV-2 antigen test in nursing home.* Enfermedades Infecciosas y Microbiología Clínica, 2021.

63. Fernandez-Montero, A., et al., *Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values.* EClinicalMedicine, 2021. **37**: p. 100954.
64. Ferté, T., et al., *Accuracy of COVID-19 rapid antigenic tests compared to RT-PCR in a student population: The StudyCov study.* Journal of Clinical Virology, 2021. **141**: p. 104878.
65. Filgueiras, P., et al., *COVID-19 Rapid Antigen Test at hospital admission associated to the knowledge of individual risk factors allow overcoming the difficulty of managing suspected patients in hospitals COVID-19 Rapid Antigen Test facilitates the management of suspected patients on hospital admission.* medRxiv [Preprint]; published January 08, 2021.
66. Fourati, S., et al., *Performance of six rapid diagnostic tests for SARS-CoV-2 antigen detection and implications for practical use.* Journal of Clinical Virology, 2021. **142**: p. 104930.
67. Frediani, J.K., et al., *Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration.* Sci Rep, 2021. **11**(1): p. 14604.
68. García-Fiñana, M., et al., *Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study.* British Medical Journal, 2021. **374**: p. n1637.
69. Gomez Marti, J.L., et al., *Differences in detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college students and children.* medRxiv [Preprint]; published February 01, 2021.
70. Gremmels, H., et al., *Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection.* EClinicalMedicine, 2020. **31**: p. 100677.
71. Gupta, A., et al., *Rapid chromatographic immunoassay-based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India.* Indian Journal of Medical Research, 2020. **153**(1): p. 126.
72. Halfon, P., et al., *An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients.* PLoS ONE, 2021. **16**(9): p. e0257817.
73. Harris, D.T., et al., *SARS-CoV-2 Rapid Antigen Testing of Symptomatic and Asymptomatic Individuals on the University of Arizona Campus.* Biomedicines, 2021. **9**(5): p. 539.
74. Herrera, V., et al., *Testing of Healthcare Workers Exposed to COVID19 with Rapid Antigen Detection.* medRxiv [Preprint]; published August 18, 2020.
75. Holzner, C., et al., *SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the emergency department of an university hospital.* Journal of Medical Virology, 2021. **93**: p. 5323–5327.
76. Homza, M., et al., *Five Antigen Tests for SARS-CoV-2: Virus Viability Matters.* Viruses, 2021. **13**(4).
77. Homza, M., et al., *Covid-19 antigen testing: better than we know? A test accuracy study.* Infectious Diseases, 2021. **53**(9): p. 661-668.
78. Houston, H., et al., *Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19.* Journal of Hospital Infection, 2021. **110**: p. 203-205.
79. Ifko, M. and M. Skvarc, *Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight Long-Term Care Facilities for the Elderly.* Healthcare, 2021. **9**(7): p. 868.
80. Iglȯi, Z., et al., *Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing site.* Emerging Infectious Diseases, 2020. **27**(5): p. 1323-1329.
81. Jääskeläinen, A.E., et al., *Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection.* Journal of Clinical Virology, 2021. **137**: p. 104785.
82. James, A.E., et al., *Performance of the BinaxNOW COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among*

symptomatic and asymptomatic healthcare employees. Infection Control and Hospital Epidemiology, 2021: p. 1-3.

83. Jegerlehner, S., et al., *Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings.* International Journal of Infectious Diseases, 2021. **109**: p. 118-122.
84. Johnson, C., et al., *Evaluation of the Panbio SARS-CoV-2 rapid antigen detection test in the Bahamas.* medRxiv [Preprint]; published July 15, 2021.
85. Jung, C., et al., *Diagnostic Accuracy of SARS-CoV-2 Antigen Detection Test in Children: A Real-Life Study.* Frontiers in Pediatrics, 2021. **9**: p. 647274.
86. Kahn, M., et al., *Performance of antigen testing for diagnosis of COVID-19: a direct comparison of a lateral flow device to nucleic acid amplification based tests.* BMC Infect Dis, 2021. **21**(1): p. 798.
87. Kanaujia, R., et al., *Rapid antigen detection kit for the diagnosis of SARS-CoV-2 - are we missing asymptomatic patients?* Indian Journal of Medical Microbiology, 2021.
88. Kannian, P., et al., *SARS-CoV2 antigen in whole mouth fluid may be a reliable rapid detection tool.* Oral Diseases, 2021. **00**: p. 1-2.
89. Karon, B.S., et al., *Analytical sensitivity and specificity of four point of care rapid antigen diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet digital PCR, and a mass spectrometric antigen assay as comparator methods.* Clinical Chemistry, 2021. **hvab138**.
90. Kenyeres, B., et al., *Comparison of four PCR and two point of care assays used in the laboratory detection of SARS-CoV-2.* Journal of Virological Methods, 2021. **293**: p. 114165.
91. Kernéis, S., et al., *Accuracy of saliva and nasopharyngeal sampling for detection of SARS-CoV-2 in community screening: a multicentric cohort study.* European Journal of Clinical Microbiology & Infectious Diseases, 2021: p. 1-10.
92. Kilic, A., B. Hiestand, and E. Palavecino, *Evaluation of Performance of the BD Veritor SARS-CoV-2 Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19.* Journal of Clinical Microbiology, 2021. **59**(5).
93. Kim, D., et al., *Development and Clinical Evaluation of an Immunochromatography-Based Rapid Antigen Test (GenBody (TM) COVAG025) for COVID-19 Diagnosis.* Viruses-Basel, 2021. **13**(5).
94. Kim, H.W., M. Park, and J.H. Lee, *Clinical Evaluation of the Rapid STANDARD Q COVID-19 Ag Test for the Screening of Severe Acute Respiratory Syndrome Coronavirus 2.* Annals of Laboratory Medicine, 2022. **42**(1): p. 100-104.
95. Kipritci, Z., et al., *Evaluation of a Visually-Read Rapid Antigen Test Kit (SGA V-Chek) for Detection of SARS-CoV-2 Virus.* Mikrobiyoloji Bulteni, 2021. **55**(3): p. 461-464.
96. Koeleman, J.G.M., et al., *Clinical evaluation of rapid point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.* European Journal of Clinical Microbiology & Infectious Diseases, 2021: p. 1-7.
97. Kohmer, N., et al., *The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro.* Journal of Clinical Medicine, 2021. **10**(2).
98. Kolwijck, E., et al., *Validation and implementation of the Panbio COVID-19 Ag rapid test for the diagnosis of SARS-CoV-2 infection in symptomatic hospital healthcare workers.* Infection Prevention in Practice, 2021. **3**(2): p. 100142.
99. Korenkov, M., et al., *Evaluation of a rapid antigen test to detect SARS-CoV-2 infection and identify potentially infectious individuals.* Journal of Clinical Microbiology, 2021. **59**(9): p. e0089621.
100. Krüger, L.J., et al., *Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2.* medRxiv [Preprint]; published October 04, 2020.
101. Krüger, L.J., et al., *The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2-Evaluation of the accuracy and ease-of-use.* PLoS ONE, 2021. **16**(5): p. e0247918.

828 102. Krüger, L.J., et al., *Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of*
829 *LumiraDx: An antigen-detecting point-of-care device for SARS-CoV-2.* Infection, 2021: p. 1-12.
830 103. Krüttgen, A., et al., *Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-*
831 *CoV-2 RT PCR kit.* Journal of Virological Methods, 2020. **288**: p. 114024.
832 104. Kumar, K.K., et al., *Pre-Operative SARS CoV-2 Rapid Antigen Test and Reverse Transcription*
833 *Polymerase Chain Reaction: A conundrum in surgical decision making.* Indian Journal of
834 Ophthalmology, 2021. **69**(6): p. 1560-1562.
835 105. Kurihara, Y., et al., *The evaluation of a novel digital immunochromatographic assay with*
836 *silver amplification to detect SARS-CoV-2.* Journal of Infection and Chemotherapy, 2021.
837 **27**(10): p. 1493-1497.
838 106. L'Huillier, A., et al., *Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in*
839 *symptomatic and asymptomatic children in the clinical setting.* Journal of Clinical
840 Microbiology, 2021. **59**(9): p. e00991-21.
841 107. Lambert-Niclot, S., et al., *Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2*
842 *Antigen in Nasopharyngeal Swabs.* Journal of Clinical Microbiology, 2020. **58**(8): p. e00977-
843 20.
844 108. Lee, J., et al., *Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and*
845 *Simulation of its Real-World Application in Korea.* Annals of Laboratory Medicine, 2021.
846 **41**(6): p. 588-592.
847 109. Leixner, G., et al., *Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting.*
848 International Journal of Infectious Diseases, 2021. **108**: p. 353-356.
849 110. Leli, C., et al., *Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted*
850 *to the Emergency Department.* International Journal of Infectious Diseases, 2021. **110**: p.
851 135–140.
852 111. Linares, M., et al., *Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in*
853 *the first 7 days after the onset of symptoms.* Journal of Clinical Virology, 2020. **133**: p.
854 104659.
855 112. Lindner, A., et al., *Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with*
856 *professional-collected nasal versus nasopharyngeal swab.* European Respiratory Journal,
857 2020. **57**(5): p. 2004430.
858 113. Lindner, A.K., et al., *Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test*
859 *with self-collected nasal swab versus professional-collected nasopharyngeal swab.* European
860 Respiratory Journal, 2021. **57**(4).
861 114. Lindner, A.K., et al., *Diagnostic accuracy and feasibility of patient self-testing with a SARS-*
862 *CoV-2 antigen-detecting rapid test.* Journal of Clinical Virology, 2021. **141**: p. 104874.
863 115. Liotti, F.M., et al., *Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen*
864 *detection in nasopharynx samples.* Clinical Microbiology and Infection, 2020. **27**: p. 487–488.
865 116. Lunca, C., et al., *Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal*
866 *samples.* medRxiv [Preprint]; published July 16, 2021.
867 117. Menchinelli, G., et al., *SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-*
868 *19: Results from a Hospital Emergency Department Testing Site.* Diagnostics, 2021. **11**(7).
869 118. Merino-Amador, P., et al., *Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-*
870 *CoV-2 infection: A multicenter evaluation study.* Journal of Clinical Virology, 2021. **143**: p.
871 104961.
872 119. Merino-Amador, P., et al., *Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-*
873 *Detection Test for the diagnosis of SARS-CoV-2 infection.* Clinical Microbiology and Infection,
874 2020. **27**(5): p. 758-761.
875 120. Mertens, P., et al., *Development and Potential Usefulness of the COVID-19 Ag Respi-Strip*
876 *Diagnostic Assay in a Pandemic Context.* Frontiers in Medicine, 2020. **7**: p. 225.
877 121. Micocci, M., et al., *Point of Care Testing using rapid automated Antigen Testing for SARS-*
878 *COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.*
879 medRxiv [Preprint]; published April 26, 2021.

122. Möckel, M., et al., *SARS-CoV-2 Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the Emergency Department.* Biomarkers, 2021. **26**(3): p. 213-220.
123. Muhi, S., et al., *Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study.* Lancet Regional Health Western Pacific, 2021. **9**: p. 100115.
124. Nalumansi, A., et al., *Field Evaluation of the Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal Samples.* International Journal of Infectious Diseases, 2020. **104**: p. 282-286.
125. Ngo Nsoga, M.T., et al., *Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2.* PLoS ONE, 2021. **16**(6): p. e0253321.
126. Nikolai, O., et al., *Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or professional collection matter?* Infectious Diseases, 2021: p. 1-6.
127. Nordgren, J., et al., *SARS-CoV-2 rapid antigen test: High sensitivity to detect infectious virus.* Journal of Clinical Virology, 2021. **140**: p. 104846.
128. Okoye, N.C., et al., *Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting.* Journal of Clinical Microbiology, 2021. **59**(4): p. e03282-20.
129. Onsongo, S.N., et al., *Field performance of NowCheck rapid antigen test for SARS-CoV-2 in Kisumu County, western Kenya.* medRxiv [Preprint]; published August 13, 2021.
130. Orsi, A., et al., *On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-COV-2 diagnostic.* Journal of Virological Methods, 2021. **295**: p. 114201.
131. Osmanodja, B., et al., *Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs.* Journal of Clinical Medicine, 2021. **10**(10).
132. Osterman, A., et al., *Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting.* Medical Microbiology and Immunology, 2021. **210**(1): p. 65-72.
133. Osterman, A., et al., *Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern.* Medical Microbiology and Immunology, 2021: p. 1-13.
134. Parada-Ricart, E., et al., *Usefulness of the antigen for diagnosing SARS-CoV-2 infection in patients with and without symptoms.* Enfermedades Infecciosas y Microbiología Clínica, 2020. **39**: p. 357-358.
135. Pekosz, A., et al., *Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture.* Clinical Infectious Diseases, 2020. **ciaa1706**.
136. Pena, M., et al., *Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals.* International Journal of Infectious Diseases, 2021. **107**: p. 201-204.
137. Pérez-García, F., et al., *Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection.* Journal of Clinical Virology, 2021. **137**: p. 104781.
138. Perez-Garcia, F., et al., *Comparative evaluation of Panbio and SD Biosensor antigen rapid diagnostic tests for COVID-19 diagnosis.* Journal of Medical Virology, 2021. **93**(9): p. 5650-5654.
139. Peto, T., *COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing.* EClinicalMedicine, 2021. **36**: p. 100924.
140. Pickering, S., et al., *Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study.* Lancet Microbe, 2021. **2**(9): p. E461-E471.
141. Pilarowski, G., et al., *Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco.* The Journal of Infectious Diseases, 2020. **223**(7): p. 1139-1144.

142. Pollock, N., et al., *Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts.* Journal of Clinical Microbiology, 2021. **59**(5): p. e00083-21.
143. Pollock, N.R., et al., *Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts.* Open Forum Infectious Diseases, 2021. **8**(7): p. ofab243.
144. Porte, L., et al., *Evaluation of two fluorescence immunoassays for the rapid detection of SARS-CoV-2 antigen - new tool to detect infective COVID-19 patients.* PeerJ, 2020. **9**: p. e10801.
145. Porte, L., et al., *Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.* International Journal of Infectious Diseases, 2020. **99**: p. 328-333.
146. Qahtani, M.A., et al., *SARS-CoV-2 rapid antigen testing for departing passengers at Vancouver international airport.* Journal of Travel Medicine, 2021. **taab085**.
147. Ristić, M., et al., *Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia.* PLoS ONE, 2021. **16**(2): p. e0247606.
148. Rottenstreich, A., et al., *Rapid antigen detection testing for universal screening for severe acute respiratory syndrome coronavirus 2 in women admitted for delivery.* American Journal of Obstetrics and Gynecology, 2021. **224**(5): p. 539-540.
149. Salvagno, G.L., et al., *Clinical assessment of the Roche SARS-CoV-2 rapid antigen test.* Diagnosis, 2021. **8**(3): p. 322-326.
150. Sberna, G., et al., *Letter of concern re: "Immunochromatographic test for the detection of SARS-CoV-2 in saliva. J Infect Chemother. 2021 Feb;27(2):384-386. doi: 10.1016/j.jiac.2020.11.016.".* Journal of Infection and Chemotherapy, 2021. **27**: p. 1129-1130.
151. Schildgen, V., et al., *Limits and opportunities of SARS-CoV-2 antigen rapid tests – an experience based perspective.* Pathogens, 2020. **10**(1): p. 38.
152. Schuit, E., et al., *Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study.* British Medical Journal, 2021. **374**: p. n1676.
153. Schwob, J.-M., et al., *Diagnostic du Covid-19 en milieu ambulatoire.* Revue médicale suisse, 2020. **17**(737): p. 862-865.
154. Scohy, A., et al., *Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.* Journal of Clinical Virology, 2020. **129**: p. 104455.
155. Seitz, T., et al., *Evaluation of rapid antigen tests based on saliva for the detection of SARS-CoV-2.* Journal of Medical Virology, 2021. **93**: p. 4161-4162.
156. Seynaeve, Y., et al., *Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2 in Nasopharyngeal Swabs.* Journal of Clinical Medicine, 2021. **10**(13): p. 2774.
157. Shah, M., et al., *Performance of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December 2020.* Clinical Infectious Diseases, 2021. **73**: p. S54–S57.
158. Shaikh, N., et al., *Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children.* Pediatrics, 2021. **148**(3): p. e2021050832.
159. Shaw, J.L.V., et al., *Evaluation of the Abbott Panbio COVID-19 Ag rapid antigen test for the detection of SARS-CoV-2 in asymptomatic Canadians.* Diagnostic Microbiology and Infectious Disease, 2021. **101**(4): p. 115514.
160. Shidlovskaya, E., et al., *The Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-CoV-2.* medRxiv [Preprint]; published March 12, 2021.
161. Shrestha, B., et al., *Sensitivity and specificity of lateral flow antigen test kits for covid-19 in asymptomatic population of quarantine centre of province 3.* Kathmandu University Medical Journal, 2020. **18**(2): p. 36-39.

162. Smith, R.D., et al., *Clinical Evaluation of Sofia Rapid Antigen Assay for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 among Emergency Department to Hospital Admissions.* Infection Control and Hospital Epidemiology, 2021: p. 1-6.
163. Šterbenc, A., et al., *Usefulness of rapid antigen testing for SARS-CoV-2 screening of healthcare workers: a pilot study.* Clinical and Experimental Medicine, 2021: p. 1-4.
164. Stohr, J., et al., *Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests for people with suspected COVID-19 in the community.* Clinical Microbiology and Infection, 2021.
165. Stokes, W., et al., *Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19.* European Journal of Clinical Microbiology & Infectious Diseases, 2021. **40**(8): p. 1721-1726.
166. Strömer, A., et al., *Performance of a Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen.* Microorganisms, 2020. **9**(1).
167. Suzuki, H., et al., *Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): a prospective observational study with 1,127 nasopharyngeal samples.* medRxiv [Preprint]; published August 04, 2021.
168. Takeda, Y., M. Mori, and K. Omi, *SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit.* medRxiv [Preprint]; published June 19, 2020.
169. Takeuchi, Y., et al., *The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan.* Journal of Infection and Chemotherapy, 2021. **27**(6): p. 890-894.
170. Takeuchi, Y., et al., *Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study.* Scientific Reports, 2021. **11**(1): p. 10519.
171. Terpos, E., I. Ntanasis-Stathopoulos, and M. Skvarc, *Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19.* Diagnostics, 2021. **11**(6): p. 995.
172. Thakur, P., et al., *Utility of Antigen-Based Rapid Diagnostic Test for Detection of SARS-CoV-2 Virus in Routine Hospital Settings.* Laboratory Medicine, 2021. **Online ahead of print**.
173. Thell, R., et al., *Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-CoV-2.* medRxiv [Preprint]; published April 22, 2021.
174. Thirion-Romero, I., et al., *Evaluation of a rapid antigen test for SARS-CoV-2 in symptomatic patients and their contacts: a multicenter study.* medRxiv [Preprint]; published May 24, 2021.
175. Tinker, S.C., et al., *Point-of-Care Antigen Test for SARS-CoV-2 in Asymptomatic College Students.* Emerging Infectious Diseases, 2021. **27**(10).
176. Toptan, T., et al., *Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread?* Journal of Clinical Virology, 2020. **135**: p. 104713.
177. Torres, I., et al., *Point-of-care evaluation of a rapid antigen test (CLINITEST) Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals.* Journal of Infection, 2021. **82**(5): p. e11–e12.
178. Torres, I., et al., *Real-life evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients.* Clinical Microbiology and Infection, 2020. **27**(4): p. 636.E1-636.E4.
179. Tsai, S.C., et al., *Real world clinical performance of SARS-CoV-2 rapid antigen tests in suspected COVID-19 cases in Taiwan.* Journal of the Formosan Medical Association, 2021. **120**(10): p. 2042-2043.
180. Turcato, G., et al., *Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report.* Journal of Infection, 2020. **82**: p. E14-E16.
181. Van der Moeren, N., et al., *Evaluation of the test accuracy of a SARS-CoV-2 rapid antigen test in symptomatic community dwelling individuals in the Netherlands.* PLoS One, 2021. **16**(5): p. e0250886.

182. Van Honacker, E., et al., *Comparison of five SARS-CoV-2 rapid antigen detection tests in a hospital setting and performance of one antigen assay in routine practice: a useful tool to guide isolation precautions?* Journal of Hospital Infection, 2021. **114**: p. 144-152.
183. Villaverde, S., et al., *Diagnostic Accuracy of the Panbio SARS-CoV-2 Antigen Rapid Test Compared with Rt-Pcr Testing of Nasopharyngeal Samples in the Pediatric Population.* The Journal of Pediatrics, 2021. **232**: p. P287-289.E4.
184. Weitzel, T., et al., *Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium.* Travel Medicine and Infectious Disease, 2020. **39**: p. 101942.
185. Weitzel, T., et al., *SARS-CoV-2 rapid antigen detection tests.* Lancet Infectious Diseases, 2021. **21**(8): p. 1067-1068.
186. Wertenauer, C., et al., *Diagnostic Efficacy of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study.* medRxiv [Preprint]; published August 07, 2021.
187. Yin, N., et al., *SARS-CoV-2 Diagnostic Tests: Algorithm and Field Evaluation From the Near Patient Testing to the Automated Diagnostic Platform.* Frontiers in Medicine, 2021. **8**: p. 380.
188. Young, B.C., D.W. Eyre, and K. Jeffery, *Use of lateral flow devices allows rapid triage of patients with SARS-CoV-2 on admission to hospital.* Journal of Infection, 2021. **82**: p. 276-316.
189. Young, S., et al., *Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test.* Journal of Clinical Microbiology, 2020. **59**(1).
190. Foundation for Innovative New Diagnostics, *FIND Evaluation of Bionote, Inc. NowCheck COVID-19 Ag Test.* External Report Version 1.5, 20 April 2021, 2020.
191. Foundation for Innovative New Diagnostics, *FIND Evaluation of RapiGEN Inc. BIOCREDIT COVID-19 Ag.* External Report Version 2.1, 10 December, 2020.
192. Foundation for Innovative New Diagnostics, *FIND Evaluation of SD Biosensor, Inc. STANDARD™ F COVID-19 Ag FIA.* External Report Version 2.1, 10 December, 2020.
193. Foundation for Innovative New Diagnostics, *FIND Evaluation of SD Biosensor, Inc. STANDARD Q COVID-19 Ag Test.* External Report Version 2.1, 10 December, 2020.
194. Foundation for Innovative New Diagnostics, *FIND Evaluation of Boditech Medical, Inc. iChroma COVID-19 Ag Test.* External Report Version 1.0, 23 February 2021, 2021.
195. Foundation for Innovative New Diagnostics, *FIND Evaluation of Joysbio (Tianjin) Biotechnology Co., Ltd. SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold).* External Report Version 1.0, 11 February 2021, 2021.
196. Foundation for Innovative New Diagnostics, *FIND Evaluation of Guangzhou Wondfo Biotech Co., Ltd Wondfo 2019-nCoV Antigen Test (Lateral Flow Method).* Public Report Version 1.0, 25 February 2021, 2021.
197. Foundation for Innovative New Diagnostics, *FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device (NASAL).* External Report Version 1.0, 11 February 2021, 2021.
198. Foundation for Innovative New Diagnostics, *FIND Evaluation of Bionote, Inc. NowCheck COVID-19 Ag Test, nasal swab.* External Report Version 1.0, 30 March 2021, 2021.
199. Foundation for Innovative New Diagnostics, *FIND Evaluation of Fujirebio Inc. Espline SARS-CoV-2.* External Report Version 1.0, 29 March 2021, 2021.
200. Foundation for Innovative New Diagnostics, *FIND Evaluation of Mologic Ltd, COVID 19 RAPID ANTIGEN TEST.* External Report Version 1.0, 23 April 2021, 2021.
201. Foundation for Innovative New Diagnostics, *FIND Evaluation of NADAL COVID-19 Ag Rapid Test.* External Report Version 1.0, 26 April 2021, 2021.
202. Foundation for Innovative New Diagnostics, *FIND Evaluation of Acon Biotech (Hangzhou) Co. Ltd; Flowflex SARS-CoV-2 Antigen Rapid Test.* External Report Version 1.0, 9 June 2021, 2021.
203. Foundation for Innovative New Diagnostics, *FIND Evaluation of Edinburgh Genetics; ActivXpress+ COVID-19 Antigen Complete Testing Kit.* External Report Version 1.0, 26 April 2021, 2021.

204. Foundation for Innovative New Diagnostics, *FIND Evaluation of Green Cross Medical Sciences Corp.; Genedia W COVID-19 Ag.* External Report Version 1.0, 25 April 2021, 2021.
205. Foundation for Innovative New Diagnostics, *FIND Evaluation of Hotgen; Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold).* External Report Version 2.0, [15 September 2021], 2021.
206. Foundation for Innovative New Diagnostics, *FIND Evaluation of Abbott; Panbio COVID-19 Ag Rapid Test Device.* Country Specific External Report Version 1.0, 28 April 2021, 2021.
207. Foundation for Innovative New Diagnostics, *FIND Evaluation of Premier Medical Corporation Pvt. Ltd; Sure Status COVID-19 Antigen Card Test.* External Report Version 1.1, 18 August 2021, 2021.
208. Foundation for Innovative New Diagnostics, *FIND Evaluation of SD Bionsensor, Inc.; STANDARD Q COVID-19 Ag Test.* External Report (Continue from V2.1) Version 1, 22 April 2021, 2021.
209. Foundation for Innovative New Diagnostics, *FIND Evaluation of SD Biosensor, Inc.; STANDARD Q COVID-19 Ag Test, nasal swab.* External Report Version 2.0, 12 April 2021, 2021.
210. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* British Medical Journal, 2021. **372**: p. n71.
211. Lindner, A., et al., *SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing.* medRxiv [Preprint]; published January 08, 2021.
212. Deerain, J., et al., *Assessment of the analytical sensitivity of ten lateral flow devices against the SARS-CoV-2 omicron variant.* J Clin Microbiol, 2021: p. jcm0247921.
213. Bekliz, M., et al., *Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant.* medRxiv [Preprint]; published December 22, 2021.
214. Kissler, S.M., et al., *Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.* N Engl J Med, 2021. **385**(26): p. 2489-2491.
215. Hay, J.A., et al., *Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant.* medRxiv [Preprint]; published January 14, 2022.
216. Adamson, B., et al., *Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series.* medRxiv [Preprint]; published January 05, 2022.
217. Marais, G., et al., *Saliva swabs are the preferred sample for Omicron detection.* medRxiv [Preprint]; published December 24, 2021.
218. Schrom, J., et al., *Direct Comparison of SARS CoV-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOW(TM)) at a Community Testing Site During an Omicron Surge.* medRxiv [Preprint]; published January 12, 2022.
219. Audigé, A., et al., *Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs.* Microorganisms, 2021. **9**(8): p. 1700.
220. Dye, C., et al., *Data sharing in public health emergencies: a call to researchers.* Bull World Health Organ, 2016. **94**(3): p. 158.
221. Modjarrad, K., et al., *Developing Global Norms for Sharing Data and Results during Public Health Emergencies.* PLoS Med, 2016. **13**(1): p. e1001935.
222. Mina, M.J., R. Parker, and D.B. Larremore, *Rethinking Covid-19 Test Sensitivity - A Strategy for Containment.* New England Journal of Medicine, 2020. **383**(22).